We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BD Receives FDA 510(k) Clearance on BD Phoenix™ Meropenem-Vaborbactam Panel
Product News

BD Receives FDA 510(k) Clearance on BD Phoenix™ Meropenem-Vaborbactam Panel

BD Receives FDA 510(k) Clearance on BD Phoenix™ Meropenem-Vaborbactam Panel
Product News

BD Receives FDA 510(k) Clearance on BD Phoenix™ Meropenem-Vaborbactam Panel


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "BD Receives FDA 510(k) Clearance on BD Phoenix™ Meropenem-Vaborbactam Panel"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BD introduces the ability to execute in vitro rapid identification (ID) and antimicrobial susceptibility testing (AST) for meropenem-vaborbactam in a new panel for the BD Phoenix™ Automated Microbiology System, which detects resistance in Enterobacteriaceae, Non-Enterobacteriaceae and most gram-positive bacteria isolates from pure culture belonging to the genera Staphylococcus, Enterococcus and Streptococcus. The BD Phoenix™ offers clinical microbiology laboratories the ability to rapidly and accurately test antimicrobial resistances or susceptibilities. BD’s rapid and reliable results for ID and AST are powered through an oxidation-reduction indicator with turbidity measurement for growth detection, as well as full on-panel antimicrobial concentrations and the BDXpert system for data analysis.
Advertisement